|
|---|
|
Pazina T,
MacFarlane AW,
Bernabei L,
Dulaimi E,
Kotcher R,
Yam C,
Bezman NA,
Robbins MD,
Ross EA,
Campbell KS,
Cohen AD. Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma.
Cancers (Basel). 2021 Jan 10;13(2)
. PMC ID:PMC7827733. |
|
MacFarlane AWth,
Yeung HM,
Alpaugh RK,
Dulaimi E,
Engstrom PF,
Dasari A,
Campbell KS,
Vijayvergia N. Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms.
Cancer Immunol Immunother. 2021 Jan 4
. |
|
Fernandez SV,
MacFarlane AW,
Jillab M,
Arisi MF,
Yearley J,
Annamalai L,
Gong YL,
Cai KQ,
Alpaugh RK,
Cristofanilli M,
Campbell KS. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
Breast Cancer Res. 2020 Dec;22(1)
:134. PMC ID:PMC7709446. |
|
Barta SK,
Zain J,
MacFarlane AW4th,
Smith SM,
Ruan J,
Fung HC,
Tan CR,
Yang Y,
Alpaugh RK,
Dulaimi E,
Ross EA,
Campbell KS,
Khan N,
Siddharta R,
Fowler NH,
Fisher RI,
Oki Y. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.
Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6)
:356-364 e3. |
|
Wagner J,
Kline CL,
Zhou LL,
Campbell KS,
MacFarlane AW,
Olszanski AJ,
Cai KQ,
Hensley HH,
Ross EA,
Ralff MD,
Zloza A,
Chesson CB,
Newman JH,
Kaufman H,
Bertino J,
Stein M,
El-Deiry WS. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.
Journal of Clinical Investigation. 2018 Jun;128(6)
:2325-2338. |
|
Finnberg NK,
Gokare P,
Lev A,
Grivennikov SI,
MacFarlane AW,
Campbell KS,
Winters RM,
Kaputa K,
Farma JM,
Abbas AE,
Grasso L,
Nicolaides NC,
El-Deiry WS. Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures.
Oncotarget. 2017 Sep;8(40)
:66747-66757. PMC ID:PMC5620133. |
|
Pazina T,
James AM,
MacFarlane AWIv,
Bezman NA,
Henning KA,
Bee C,
Graziano RF,
Robbins MD,
Cohen AD,
Campbell KS. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms.
OncoImmunology. 2017 Sep;6(9)
:e1339853. PMC ID:PMC5599094. |
|
MacFarlane AWIv,
Jillab M,
Smith MR,
Alpaugh RK,
Cole ME,
Litwin S,
Millenson MM,
Al-Saleem T,
Cohen AD,
Campbell KS. NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors.
OncoImmunology. 2017 ;6(7)
:e1330235. PMC ID:PMC5543845. |
|
Ge MQ,
Kokalari B,
Flayer CH,
Killingbeck SS,
Redai IG,
MacFarlane AWth,
Hwang JW,
Kolupoti A,
Kemeny MD,
Campbell KS,
Haczku A. Cutting Edge: Role of NK Cells and Surfactant Protein D in Dendritic Cell Lymph Node Homing: Effects of Ozone Exposure.
J Immunol. 2016 Jan 15;196(2)
:553-7. PMC ID:PMC4707083. |
|
Kaileh M,
Vazquez E,
MacFarlane AWth,
Campbell K,
Kurosaki T,
Siebenlist U,
Sen R. mTOR-Dependent and Independent Survival Signaling by PI3K in B Lymphocytes.
PLoS One. 2016 Jan;11(1)
:e0146955. PMC ID:PMC4718598. |
|
Ni MJ,
MacFarlane AW,
Toft M,
Lowell CA,
Campbell KS,
Hamerman JA. B-cell adaptor for PI3K (BCAP) negatively regulates Toll-like receptor signaling through activation of PI3K.
Proceedings of the National Academy of Sciences of the United States of America. 2012 Jan;109(1)
:267-272. PMC ID:PMC3252908. |
|
MacFarlane AW,
Oesterling JF,
Campbell KS. Measuring intracellular calcium signaling in murine NK cells by flow cytometry.
Methods Mol Biol. 2010 ;612
:149-57. PMC ID:PMC2798144. |
|
MacFarlane AWth,
Yamazaki T,
Fang M,
Sigal LJ,
Kurosaki T,
Campbell KS. Enhanced NK-cell development and function in BCAP-deficient mice.
Blood. 2008 Jul 1;112(1)
:131-40. |
|
MacFarlane AWth,
Campbell KS. Signal transduction in natural killer cells.
Curr Top Microbiol Immunol. 2006 ;298
:23-57. |
|
MacFarlane AW,
Campbell KS. Signal transduction in natural killer cells.
Immunobiology of natural killer cell receptors. 2006
:23-58. |
|
Faculty
Publications
